Orofacial dyskinesia associated with the use of levofloxacin

To describe a case of orofacial dyskinesia in a patient treated with levofloxacin for acute diverticulitis.

A 77-year-old woman with mild renal insufficiency was admitted with acute diverticulitis. She was initiated on levofloxacin 500 mg IV daily and metronidazole 500 mg IV every 8 hours. On day 4 of treatment, she experienced involuntary, rhythmic facial grimacing accompanied by periodic cervical muscular contractures. Her speech became dysarthric, interrupted by uncontrolled facial and tongue movements, all findings consistent with orofacial dyskinesia. Antibiotics were discontinued, and symptoms resolved after administration of diphenhydramine and lorazepam IV.

Fluoroquinolone-associated central nervous system (CNS) toxicities are infrequently observed. They are most commonly associated with ciprofloxacin and are thought to be related to inhibition of γ-aminobutyric acid receptors and activation of N-methyl-d-aspartate receptors. Orofacial dyskinesia has previously been reported primarily with second-generation fluoroquinolones, with only a single case report implicating a third-generation fluoroquinolone. To our knowledge, we report the second case of orofacial dyskinesia with a third-generation fluoroquinolone, the first such case associated with levofloxacin. The orofacial dyskinesia experienced in this case was categorized as probably related to levofloxacin, as assessed by the Naranjo adverse drug reaction probability assessment tool. Contributing factors likely included age and renal function.

Although rare, CNS toxicities such as orofacial dyskinesia have been reported with levofloxacin. Patients on fluoroquinolones of advanced age and with renal insufficiency should be monitored closely for such toxicities.